|Table of Contents|

To explore the relationship between miR-181a and endocrine therapy efficiency of ER positive breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 04
Page:
573-577
Research Field:
Publishing date:

Info

Title:
To explore the relationship between miR-181a and endocrine therapy efficiency of ER positive breast cancer
Author(s):
Yan Shunchao1; Jiao Xin2; Li Na1; Du Yangfan1
1.Department of Oncology,Shengjing Hospital of China Medical University,Liaoning Shenyang 110022,China;2.Department of Respiratory Medicine,Shenyang Chest Hospital,Liaoning Shenyang 110044,China.
Keywords:
miR-181a; breast cancer; endocrine therapy; efficiency
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2020.04.011
Abstract:
Objective：To investigate the expression of miR-181a and endocrine-therapy sensitivity of estrogen receptor (ER) positive breast cancer.Methods:We constructed tamoxifen-resistant MCF-7 cell line using gradient incremental method.Cells proliferation was measured using colony formation assay.The expression of miR-181a was determined by RT-PCR.The prognostic value of miR-181a in breast cancer was analyzed using Kaplan-Meier Plotter.Results:We successfully constructed a cell line resistant to tamoxifen (TAM-R).RT-PCR results showed that the expression of miR-181a was higher in tamoxifen induced and primary resistance cell lines than tamoxifen sensitive cell line.High expression of miR-181a predicted significantly poorer overall survival (OS) in ER-positive but not ER-negative breast cancer.Further analysis showed that high expression of miR-181a was associated with poorer OS in endocrine-therapy treated ER-positive breast cancer but not in ER-positive breast cancer without endocrine-therapy treatment.Conclusion:High expression of miR-181a predicted less sensitive to endocrine therapy in ER positive breast cancer.miR-181a might be a promising predictor of the efficacy of endocrine therapy.

References:

［1］ Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
［2］ Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［3］ HAN BJ，PANG H.Advance of the relationship between microＲNA-181 family and malignant tumor ［J］.Modern Oncology,2018,28(3):459-462.［韩宝娟，庞慧.miRNA-181家族与恶性肿瘤关系的研究进展［J］.现代肿瘤医学,2018,28(3):459-462.］
［4］ Lim LP,Glasner ME,Yekta S,et al.Vertebrate microRNA genes［J］.Science,2003,299(5612):1540.
［5］ Ota D,Mimori K,Yokobori T,et al.Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients［J］.I Int J Oncol,2011(38):955-962.
［6］ Ling H,Fabbri M,Calin GA.MicroRNAs and other non-coding RNAs as targets for anticancer drug development［J］.Nat Rev Drug Discov,2013（12）:847-865.
［7］ Wang Y,Yu Y,Tsuyada A,et al.Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM［J］.Oncogene,2011(30):1470-1480.
［8］ Neel JC,Lebrun JJ.Activin and TGF-beta regulate expression of the microRNA-181 family to promote cell migration and invasion in breast cancer cells［J］.Cell Signal,2013(25):1556-1566.
［9］ Yang C,Tabatabaei SN,Ruan X,et al.The dual regulatory role of miR-181a in breast cancer［J］.Cell Physiol Biochem,2017,44(3):843-856.
［10］ Niu J,Xue A,Chi Y,et al.Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer［J］.Oncogene,2016,35(10):1302.
［11］ Escrivá-de-Romaní S,Arumí M,Bellet M,et al.HER2-positive breast cancer:Current and new therapeutic strategies［J］.The Breast,2018(39):80-88.
［12］ Taylor MA,Sossey-Alaoui K,Thompson CL,et al.TGF-β upregulates miR-181a expression to promote breast cancer metastasis［J］.The Journal of Clinical Investigation,2013,123(1):150-163.
［13］ Strotbek M,Schmid S,Sánchez-González I,et al.miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer［J］.International Journal of Cancer,2017,140(10):2310-2320.
［14］ Larsen SL,Laenkholm AV,Duun-Henriksen AK,et al.Src drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment［J］.PLoS One,2015,10(2):e0118346.
［15］ LIU C,LIU WG,ZHNAG L,et al.Research progress of signal pathways associated with endocrine therapy resistance in breast cancer［J］.Modern Oncology,2017,25(9):1480-1485.［刘程，刘伟光，张磊，等.乳腺癌内分泌治疗耐药相关信号通路的研究进展［J］.现代肿瘤医学，2017,25(9):1480-1485.］

Memo

Memo:
National Natural Science Foundation of China（No.81302313）;国家自然科学基金项目（编号：81302313）；辽宁省自然科学基金指导计划（编号：20170540995）;沈阳市中青年科技创新人才支持计划项目（编号：RC170545）
Last Update: 2020-01-14